Actithera Secures $75.5 Million in Oversubscribed Series A Financing to Pioneer Precision Radioligand Therapy
San Francisco, CA – July 9, 2025 – Actithera, a pioneering biopharmaceutical company dedicated to advancing the field of precision radioligand therapy, announced today the successful closing of its Series A financing round, raising an impressive $75.5 million. This substantial funding, which was significantly oversubscribed, signifies strong investor confidence in Actithera’s innovative approach to targeting and treating a wide range of challenging diseases.
The Series A funding round was led by a prominent group of life science investors, with participation from new and existing financial partners. The capital infusion will be instrumental in propelling Actithera’s robust pipeline forward, enabling the company to advance its novel radioligand candidates through critical preclinical and clinical development stages. Furthermore, the funding will support the expansion of Actithera’s proprietary platform technologies, which are designed to enhance the precision and efficacy of radioligand therapies.
Radioligand therapy represents a highly targeted approach to cancer treatment, utilizing radioactive isotopes bound to molecules that specifically seek out and bind to cancer cells. This method allows for the delivery of therapeutic radiation directly to tumor sites while minimizing damage to healthy tissues, thereby offering a more precise and potentially less toxic treatment option. Actithera’s innovative platform aims to further refine this approach, promising enhanced tumor targeting, improved therapeutic indices, and broader applicability across various cancer types and other diseases.
“We are thrilled to announce the successful closing of our Series A financing, a significant milestone that underscores the immense potential of our precision radioligand therapy platform,” said [Insert Name and Title of Actithera CEO/Spokesperson, if available, otherwise use a general statement like “the leadership team at Actithera”]. “This funding will empower us to accelerate the development of our groundbreaking therapies and bring much-needed innovation to patients battling serious diseases. We are grateful for the strong support from our investors, who share our vision for redefining cancer treatment through targeted molecular medicine.”
The investment will also support the growth of Actithera’s scientific and operational teams, attracting top talent to further strengthen its research and development capabilities. The company’s strategic focus includes expanding its portfolio of investigational radioligand therapies and exploring new therapeutic applications for its platform technology.
With this significant financial backing, Actithera is well-positioned to make substantial contributions to the radioligand therapy landscape, offering new hope and improved outcomes for patients worldwide. The company is committed to advancing its pipeline with a patient-centric approach, driven by scientific rigor and a dedication to innovation.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy’ at 2025-07-09 07:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.